Accreditation Information

CME

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CEC designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Other

Creative Educational Concepts, Inc. certifies this activity for 1.00 hour of participation.

Objectives

  1. Review current status of checkpoint inhibitor use in urothelial cancer
  2. Explore future directions of immunotherapy in urothelial cancer, including the role of sequential therapy and multimodal and/or combination regimens.
  3. Examine the role of checkpoint inhibitors in non-muscle-invasive, BCG-resistant or BCG-ineligible disease.

Target Audience

This activity is designed to meet the educational needs of urologists and urologic oncologists attending the 2018 Society of Urologic Oncology annual meeting.

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners

Joan B. Fowler, PharmD, BCPP–has no relevant financial relationships to disclose in relation to the content of this activity.

Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters

Arjun V. Balar, MD—has disclosed that he is a consultant for AstraZeneca/MedImmune, Genentech, Merck, Pfizer, and Roche. He also receives grant/research support from Genentech, Merck, and Roche.

Ashish M. Kamat, MD, MBBS, FACS—has disclosed that he is a consultant for Abbott, AstraZeneca, Genentech, and Merck. He also receives grant/ research support from FKD Therapies, Merck, and Photocure.

Neal D. Shore, MD, FACS—has disclosed that he is a consultant for and receives grant/research support from AstraZeneca, EMD Serono, FKD Therapies, Genentech, Merck, and Pfizer.

Peer Reviewer

Bishoy Morris Faltas, MD (Weill Cornell Medicine, New York, NY)—has no relevant financial relationships to disclose in relation to the content of this activity.